Abstract: The invention relates to new piperazinyl-substituted pyridylalkane, alkene, and alkine acid amides substituted with saturated or one or several-fold unsaturated hydrocarbon residue in the carboxylic acid group according to the general formula (I) as well as methods for the production of these compounds, medicaments containing these and their production as well as their therapeutic use, especially as cytostatic agents and immunosuppressive agents, for example in the treatment or prevention of various types of tumors and control of immune reactions such as autoimmune diseases.

Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.

Abstract: The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression.

Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.

Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.

Abstract: The invention relates to new piperidinyl-substituted pyridyl carboxamides of the general formula (I), wherein the structure element E has meanings (E1) or (E2) and whereby the heterocyclic ring can optionally have a double bond. These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum.

Abstract: New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.

Abstract: New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.

Abstract: The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression.

Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.

Abstract: A pharmaceutical composition for oral administration contains naloxone-, N-methylnaloxone- and/or N-methylnaltrexone-containing particles which release the active substance depending on the ambient pH. This ensures the liberation of the active substance over the whole gastrointestinal tract. The side effects caused by the use of analgesic opioids, such as constipation, are thus eliminated without reducing the analgesic effect.

Abstract: The invention relates to a medicament containing a standardized dry extract of horse chestnut seeds which is active against various types of edema and diseases of the venous circulatory system and to a process for manufacturing this medicament. The dry seed extract is processed to the form of pellets which can be coated to obtain sustained release of the agent. In this way satisfying therapeutical blood levels of the triterpene glycosides as agent are achieved. The finished medicament according to the invention can best be provided as hard gelatin capsule or matrix tablet containing the extract pellets.

Abstract: The present invention relates to methods for the production of E-1-?4'-(2-dimethylaminoethoxy)-phenyl!-1-(3'-hydroxyphenyl)-2-phenyl-1-bu tene of formula (I) which comprises heating the compound of formula (II) in the presence of an organic solvent and HCl gas and cooling the reaction to obtain the compound of formula (IIIa), and then heating the isolated compound of formula (IIIa) in the presence of sulfuric acid or hydrochloric acid to obtain the compound according to formula (I).

Abstract: A new modification of Lifibrol is described with a melting point of 132.degree. C.-138.degree. C. particularly from 134.degree. C.-136.degree. C. and a primary peak in an IR spectrum at a wave number of 3,200-3,400, preferably 3,250-3,350. The new modification of Lifibrol (modification II) is distinguished in that it allows for good crystallization and, therefore, can be formulated without problems on a large industrial scale for tablets of acceptable size and high stability.

Abstract: The present invention relates to a transdermal therapeutical system for the administration of physostigmine to the skin via a backing layer which is impermeable to active substances, an active substance deposit comprising at least one auxiliary agent with supporting and distributing function in the form of a textile fabric material, a matrix surrounding said deposit from all sides, and optionally a removable protective layer, the matrix of which comprises 10-90%-wt polymeric material selected from the group consisting of polymers on the basis of acrylate and/or methacrylate and esters of hydrogenated colophonium, 0-30%-wt softener on the basis of hydrocarbons and/or esters, and that the active substance deposit immediately after its production comprises 15-85%-wt of a 0.1-70%-wt physostigmine solution.

Abstract: The preparation of the pure enantiomers of LIFIBROL and its alkyl esters is achieved with surprisingly good yield by reacting the pure enantiomeric forms of S(-) R(+)-4-(4-tert.butylphenyl)-1,2-epoxy butane with 4-hydroxybenzoic acid alkyl ester at elevated temperature in DMF and in the presence of 4-hydroxybenzoic acid alkyl ester sodium salt. Thereafter, the raw reaction product is separated. Either the stereochemically pure LIFIBROL ester is then recovered by recrystallization or the precipitated LIFIBROL enantiomer is made in pure crystalline form by mild alkaline saponification and subsequent acidification.

Abstract: Remedies for bone diseases comprising, as active ingredient, droloxifene or a salt thereof.

Abstract: p-Oxybenzoic acid derivatives of the general formula (1) ##STR1## their physiologically compatible salts and their enantiomeric and diastereomeric forms have hypolipemic properties and are therefore suitable for the preparation of drugs with hypolipemic action.

Abstract: The invention relates to p-oxibenzoic acid derivatives of the general formula (1) where: ##STR1## their diastereomers and enantiomers in pure form or as mixture of stereoisomeric forms and their physiologically compatible salts, a process for the preparation thereof and the use thereof for preparing drugs with hypolipemic effect.

Abstract: The present invention relates to a transdermal therapeutical system for the administration of physostigmine to the skin via a cover layer which is impermeable to active substances, a pressure-sensitive adhesive reservoir layer, and optionally a removable protective layer, said reservoir layer consisting of 10-90% polymeric material selected from the groups consisting of block copolymers on the basis of styrene and 1,3-dienes, polyisobutylenes, polymers on the basis of acrylates and/or methacrylates and esters of hydrogenated colophonium, 0-30%-wt softeners on the basis of hydrocarbons and/or esters, and 0.1-20%-wt physostigmine.